ECM Powder Self-Assembly for Scaffold-Free Artificial Tissue Fabrication

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current tissue engineering methods face challenges in fabricating artificial tissues without scaffolds and differentiation-inducing additives, particularly in achieving large sizes and uniform cell distribution, while also dealing with biocompatibility and immune response issues with synthetic materials.

Innovation Solution

The method involves decellularizing and powdering tissue-derived extracellular matrix (ECM) to create a cell-ECM powder self-assembly by adding the ECM powder to stem cells, allowing for self-assembly into three-dimensional artificial tissues without the need for separate scaffolds or additives, using ECM powders derived from various tissues like cartilage, meniscus, and small intestine submucosa.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If scaffold-free method is used to fabricate artificial tissue, then the need for scaffolds is eliminated, but the tissue size is limited to less than 1 cm due to diffusion limitations

Engineering Contradiction:

Improveelimination of scaffold requirementVSAvoidtissue size

Core Design Contradiction:

Ease of manufactureVSVolume of moving object

Solution Approach 1:

The patent uses growth factors and cytokines as intermediary substances to mediate cell differentiation and tissue formation. These biochemical mediators enable cells to self-organize into functional tissues without requiring physical scaffolds, while also supporting the development of larger tissue structures through controlled biological signaling.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent employs rotating culture techniques that change physical parameters (rotation speed, culture conditions) to control cell aggregation and tissue formation. By adjusting rotation parameters, the system can produce tissues of controlled sizes up to 1 cm or more, overcoming the diffusion limitation while maintaining scaffold-free conditions.

Inventive Principle:

Principle #35Parameter changes

2Device complexity

If scaffold-free method is used to fabricate artificial tissue, then the process is simplified, but a large amount of cells are required compared to scaffold method

Engineering Contradiction:

Improveprocess simplificationVSAvoidcell quantity required

Core Design Contradiction:

Device complexityVSQuantity of substance

Solution Approach 1:

The patent performs preliminary cell expansion and pre-differentiation in controlled culture conditions before the main tissue fabrication process. This preliminary action increases cell density and differentiation efficiency, reducing the total cell quantity needed for scaffold-free tissue production while maintaining process simplicity.

Inventive Principle:

Principle #10Preliminary action

3Manufacturing precision

If growth factors are added to induce differentiation in scaffold-free method, then target tissue formation is achieved, but cost and production stability are reduced

Engineering Contradiction:

Improvedifferentiation controlVSAvoidproduction cost and stability

Core Design Contradiction:

Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent uses controlled, partial addition of growth factors at specific stages rather than continuous high-concentration treatment. This partial action achieves sufficient differentiation control while minimizing the total amount of expensive growth factors required, thereby reducing production cost and improving stability.

Inventive Principle:

Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach enables the formation of high-quality, uniform artificial tissues and organs up to 1 cm in size with controlled size and biochemical properties similar to the original tissues, suitable for cell therapy and implants, without the need for additional differentiation-inducing factors.

Implementation Method 1

fabrication of an extracellular matrix-induced self-assembly

Methodology Applied

Scientific EffectSelf-assembly: Self-Assembly

Data Source

PatentUS20220340867A1Method for fabrication of extracellular matrix-induced self-assembly and fabrication of artificial tissue using same

Publication Date: 2022.10.27 AVANTRIX

AI summary

The present invention relates to a method for fabrication of an extracellular matrix-induced self-assembly and to fabrication of an artificial tissue using same. The method for fabrication of an extracellular matrix-induced self-assembly comprise the steps of: (a) decellularizing and powdering a tissue-derived extracellular matrix (ECM); and (b) adding the decellularized extracellular matrix powder to cells and culturing the cells to form a cell-extracellular matrix powder self-assembly. Accordingly, the self-assembly has characteristics similar to those of extracellular matrix tissues and can be fabricated into three-dimensional artificial tissues 1 cm or greater in size, thus finding advantageous applications as a cell therapy product and an artificial tissue implant.